PL2073842T3 - Zastosowanie ludzkich komórek pochodzących z białaczki szpikowej do ekspresji przeciwciał - Google Patents

Zastosowanie ludzkich komórek pochodzących z białaczki szpikowej do ekspresji przeciwciał

Info

Publication number: PL2073842T3
Authority: PL; Poland
Prior art keywords: antibodies; expression; human cells; myeloid leukaemia; leukaemia origin
Prior art date: 2006-09-10

Application number

PL07818090T

Other languages

English (en)

Other versions

PL2073842T5 (pl

Inventor

Steffen Goletz

Antje Danielczyk

Hans Baumeister

Renate Stahn

Anja LÖFFLER

Lars Stöckl

Original Assignee

Glycotope Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-10

Filing date

2007-09-10

Publication date

2015-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39157600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2073842(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-18 Priority claimed from EP06090171A external-priority patent/EP1900750A1/en

2006-10-13 Priority claimed from EP06090190A external-priority patent/EP1911766A1/en

2007-09-10 Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh

2015-06-30 Publication of PL2073842T3 publication Critical patent/PL2073842T3/pl

2024-12-02 Publication of PL2073842T5 publication Critical patent/PL2073842T5/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1735—Mucins, e.g. human intestinal mucin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Public Health (AREA)
Reproductive Health (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Mycology (AREA)
Marine Sciences & Fisheries (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL07818090.8T 2006-09-10 2007-09-10 Zastosowanie ludzkich komórek pochodzących z białaczki szpikowej do ekspresji przeciwciał PL2073842T5 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
EP06090162		2006-09-10
EP06090171A EP1900750A1 (en)	2006-09-18	2006-09-18	Fully human high yield production system for improved antibodies
EP06090190A EP1911766A1 (en)	2006-10-13	2006-10-13	Use of human cells of myeloid leukaemia origin for expression of antibodies
EP07090094		2007-05-04
EP07818090.8A EP2073842B2 (en)	2006-09-10	2007-09-10	Use of human cells of myeloid leukaemia origin for expression of antibodies
PCT/EP2007/007877 WO2008028686A2 (en)	2006-09-10	2007-09-10	Use of human cells of myeloid leukaemia origin for expression of antibodies

Publications (2)

Publication Number	Publication Date
PL2073842T3 true PL2073842T3 (pl)	2015-06-30
PL2073842T5 PL2073842T5 (pl)	2024-12-02

Family

ID=39157600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07818090.8T PL2073842T5 (pl)	2006-09-10	2007-09-10	Zastosowanie ludzkich komórek pochodzących z białaczki szpikowej do ekspresji przeciwciał

Country Status (25)

Country	Link
US (3)	US9051356B2 (pl)
EP (5)	EP3539981A1 (pl)
JP (3)	JP5767779B2 (pl)
KR (3)	KR20150126730A (pl)
CN (1)	CN103436574B (pl)
AU (1)	AU2007294122B2 (pl)
BR (1)	BRPI0716997B8 (pl)
CA (1)	CA2662226C (pl)
CU (1)	CU23791A3 (pl)
CY (1)	CY1116279T1 (pl)
DK (2)	DK2428224T3 (pl)
EA (1)	EA017622B1 (pl)
ES (2)	ES2620261T3 (pl)
FI (1)	FI2073842T4 (pl)
HR (1)	HRP20150307T1 (pl)
IL (1)	IL197459A (pl)
MX (1)	MX2009002388A (pl)
NZ (1)	NZ575974A (pl)
PL (1)	PL2073842T5 (pl)
PT (1)	PT2073842E (pl)
RS (1)	RS53861B1 (pl)
SG (1)	SG174792A1 (pl)
SI (1)	SI2073842T1 (pl)
WO (1)	WO2008028686A2 (pl)
ZA (1)	ZA201001903B (pl)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3528611B2 (ja) *	1998-07-16	2004-05-17	Ｊｆｅスチール株式会社	結束材の切断方法及びその装置
EP3539981A1 (en)	2006-09-10	2019-09-18	Glycotope GmbH	Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl)	2006-11-10	2015-06-30	Glycotope Gmbh	Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008135259A2 (en) *	2007-05-04	2008-11-13	Glycotope Gmbh	Antibody molecule composition
GB0812277D0 (en) *	2008-07-04	2008-08-13	Fusion Antibodies Ltd	Antibody and uses thereof
KR20110119702A (ko)	2009-01-22	2011-11-02	모멘타 파머슈티컬스 인코포레이티드	Ｃｈｏ 세포에서 유도된 글리코단백질 생성물에서의 갈락토오스-알파-1,3-갈락토오스-함유 ｎ-글리칸
US20120100576A1 (en)	2009-07-08	2012-04-26	Glycotope Gmbh	Perfusion bioreactor
EP2281844A1 (en)	2009-07-31	2011-02-09	Glycotope GmbH	MUC 1 antibodies
WO2012016576A1 (en)	2010-08-04	2012-02-09	Glycotope Gmbh	Improved recombinant human follicle-stimulating hormone
US9051370B2 (en)	2010-08-10	2015-06-09	Glycotope Gmbh	Humanized EGFR antibodies
PT2603528T (pt) *	2010-08-10	2016-12-01	Glycotope Gmbh	Anticorpos glicosilados em fab
EP2603527A1 (en)	2010-08-10	2013-06-19	Glycotope GmbH	Humanized egfr antibodies
ES2624479T3 (es)	2010-12-21	2017-07-14	Glycotope Gmbh	Métodos para cultivar células de leucemia mieloide humana y células derivadas de esta
BR112013027119A8 (pt)	2011-04-21	2018-03-06	Seattle Genetics Inc	novos conjugados ligante-droga (adcs) e uso dos mesmos
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN104168913A (zh) *	2011-08-10	2014-11-26	法国化学与生物科技实验室	高半乳糖基化抗体
ES2686313T3 (es)	2011-08-22	2018-10-17	Glycotope Gmbh	Microorganismos que portan un antígeno tumoral
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
BR112014032169A2 (pt) *	2012-07-18	2017-08-01	Glycotope Gmbh	tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
CA2897505A1 (en)	2013-01-18	2014-07-24	Glycotope Gmbh	Peptides for enhancing protein expression
EP3594230A1 (en) *	2013-02-13	2020-01-15	Laboratoire Français du Fractionnement et des Biotechnologies	Highly galactosylated anti-tnf-alpha antibodies and uses thereof
CN105358577A (zh) *	2013-02-13	2016-02-24	法国化学与生物科技实验室	具有经修饰的糖基化的西妥昔单抗及其用途
US10034921B2 (en)	2013-02-13	2018-07-31	Laboratoire Français Du Fractionnement Et Des Biotechnologies	Proteins with modified glycosylation and methods of production thereof
WO2014125377A2 (en) *	2013-02-13	2014-08-21	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Highly galactosylated anti-her2 antibodies and uses thereof
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
WO2014143343A1 (en)	2013-03-14	2014-09-18	Abbott Laboratories	Hcv core lipid binding domain monoclonal antibodies
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP2016512241A (ja)	2013-03-14	2016-04-25	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
MX362075B (es)	2013-03-14	2019-01-07	Abbott Lab	Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI670279B (zh)	2013-03-15	2019-09-01	Alder Biopharmaceuticals, Inc.	抗體純化及純度監測
CA2908819A1 (en)	2013-04-22	2014-10-30	Glycotope Gmbh	Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
US10208125B2 (en) *	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) *	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
RU2698697C2 (ru)	2013-12-23	2019-08-29	Байер Фарма Акциенгезельшафт	Конъюгаты связующего (ADC) с ингибиторами KSP
BR112016019893B1 (pt) *	2014-03-05	2023-02-14	Ultragenyx Pharmaceutical Inc	Composição
US20150307546A1 (en) *	2014-04-29	2015-10-29	Georgia Tech Research Corporation	Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation
CN105820248A (zh) *	2015-01-07	2016-08-03	上海张江生物技术有限公司	一种新型抗egfr单克隆抗体的制备方法及应用
LU92659B1 (en) *	2015-02-23	2016-08-24	Glycotope Gmbh	Glycooptimized antibody drug conjugates
LT3277807T (lt)	2015-03-31	2020-01-10	Glycotope Gmbh	Eukariotiniai ekspresijos vektoriai, apimantys globino genų klasterių reguliavimo elementus
FR3034420A1 (fr)	2015-03-31	2016-10-07	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-cd303
WO2016198499A1 (en)	2015-06-09	2016-12-15	Glycotope Gmbh	IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
JP6971858B2 (ja)	2015-06-22	2021-11-24	バイエルファーマアクチエンゲゼルシャフト	酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
EP3313523A2 (en)	2015-06-23	2018-05-02	Bayer Pharma Aktiengesellschaft	Targeted conjugates of ksp inhibitors
WO2016207328A1 (en)	2015-06-24	2016-12-29	Glycotope Gmbh	PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
FR3038517B1 (fr)	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Utilisation de fragments fc modifies en immunotherapie
EP3347380B1 (en) *	2015-09-11	2024-09-25	Nascent Biotech, Inc.	Enhanced delivery of drugs to the brain
WO2017060322A2 (en)	2015-10-10	2017-04-13	Bayer Pharma Aktiengesellschaft	Ptefb-inhibitor-adc
US20170114127A1 (en)	2015-10-22	2017-04-27	Massachusetts Institute Of Technology	Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
WO2017162733A1 (en) *	2016-03-22	2017-09-28	Glycotope Gmbh	Iga antibodies with enhanced stability
JP7251981B2 (ja)	2016-03-24	2023-04-04	バイエルファーマアクチエンゲゼルシャフト	酵素開裂基を有する細胞毒性活性剤のプロドラッグ
EP3919518A1 (en)	2016-06-15	2021-12-08	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3472338B1 (en)	2016-06-20	2024-05-22	Octapharma AG	Means and methods for modifying multiple alleles
FR3060395B1 (fr)	2016-12-16	2019-05-24	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Combinaison d'anticorps anti-cd303 et anti-her2
FR3060394B1 (fr)	2016-12-16	2019-05-24	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Combinaison d'anticorps anti-cd303 et anti-amhrii
CN110312534B (zh)	2016-12-21	2023-04-04	拜耳制药股份公司	具有酶促可裂解基团的抗体-药物-缀合物(adc)
CN110072556B (zh)	2016-12-21	2023-05-02	拜耳制药股份公司	具有ksp抑制剂的特异性抗体药物缀合物(adc)
US12059472B2 (en)	2016-12-21	2024-08-13	Bayer Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US20190343953A1 (en)	2017-01-27	2019-11-14	Glycotope Gmbh	Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP6829357B2 (ja) *	2017-03-17	2021-02-10	住友ベークライト株式会社	抗体の糖鎖検出法
WO2018178047A1 (en)	2017-03-29	2018-10-04	Glycotope Gmbh	Multispecific antibody constructs binding to muc1 and cd3
US20200148785A1 (en) *	2017-03-29	2020-05-14	Glycotope (GmbH)	Pd-l1 and ta-muc1 antibodies
WO2018178046A1 (en)	2017-03-29	2018-10-04	Glycotope Gmbh	Humanized anti-cd40 antibodies
EP3679066A4 (en)	2017-09-06	2021-06-09	Airway Therapeutics, Inc.	METHOD AND COMPOSITIONS FOR MANUFACTURING SURFACTANT PROTEIN D (SP-D)
CN112040967A (zh) *	2017-09-06	2020-12-04	气道治疗公司	用于制备表面活性蛋白d(sp-d)的方法、组合物和细胞
CA3090407A1 (en)	2018-03-01	2019-09-06	Glycotope Gmbh	Fusion protein constructs comprising an anti-muc1 antibody and il-15
SG11202010496WA (en)	2018-05-18	2020-12-30	Daiichi Sankyo Co Ltd	Anti-muc1 antibody-drug conjugate
CN114450306B (zh) *	2019-07-26	2024-04-05	Abl生物公司	抗egfr/抗4-1bb双特异性抗体及其用途
SG11202110968VA (en)	2019-12-06	2021-10-28	Regeneron Pharma	Anti-vegf protein compositions and methods for producing the same
AU2021268026A1 (en)	2020-05-08	2023-01-19	Regeneron Pharmaceuticals, Inc.	VEGF traps and mini-traps and methods for treating ocular disorders and cancer
AU2021298824A1 (en)	2020-06-30	2023-01-19	Pentixapharm Ag	Humanized antibodies against lewis Y
CA3253998A1 (en)	2022-03-16	2023-09-21	Pentixapharm Ag	ANTIBODIES DIRECTED AGAINST LYPD3
WO2025099324A1 (en)	2023-11-10	2025-05-15	Tixapharm Ag	Antibodies against cd44
WO2025132836A1 (en)	2023-12-19	2025-06-26	Pentixapharm Ag	Antibodies against cd24

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
AU2353384A (en) *	1983-01-19	1984-07-26	Genentech Inc.	Amplification in eukaryotic host cells
KR850004274A (ko) *	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
US4931275A (en) *	1985-12-02	1990-06-05	Yeda Research & Development Co., Ltd.	Anti-tumor vaccines and their preparation
US5683674A (en) *	1987-01-07	1997-11-04	Imperial Cancer Research Technology Ltd.	Antibody against human mucin core protein and method of preparing and using same
CA2100671C (en)	1991-02-27	1999-02-02	James S. Huston	Serine rich peptide linkers
JP3698370B2 (ja)	1992-04-13	2005-09-21	ダナ−ファーバーキャンサーインスティチュートインク	癌腫抗原用抗体
US5804187A (en) *	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
JP3626187B2 (ja)	1993-06-07	2005-03-02	バイカルインコーポレイテッド	遺伝子治療に適するプラスミド
DE4329004A1 (de)	1993-08-28	1995-03-09	Max Delbrueck Centrum	Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
AU7965694A (en) *	1993-10-15	1995-05-04	Curators Of The University Of Missouri, The	Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5997873A (en) *	1994-01-13	1999-12-07	Mount Sinai School Of Medicine Of The City University Of New York	Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) *	1994-03-16	1999-10-05	Mount Sinai School Of Medicine Of The City University Of New York	Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5888773A (en) *	1994-08-17	1999-03-30	The United States Of America As Represented By The Department Of Health And Human Services	Method of producing single-chain Fv molecules
US5739277A (en) *	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
CA2225460A1 (en)	1995-06-23	1997-01-09	Winston Campbell Patterson	Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB9603256D0 (en) *	1996-02-16	1996-04-17	Wellcome Found	Antibodies
EP0906444A1 (de)	1996-04-19	1999-04-07	Gabriele Pecher	Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
ATE550042T1 (de) *	1997-11-20	2012-04-15	Vical Inc	Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
US5948646A (en) *	1997-12-11	1999-09-07	Fordham University	Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AUPP816899A0 (en)	1999-01-14	1999-02-11	Food Technology Innovations Pty Limited	Improved microbial products
EP1399538A4 (en)	1999-03-02	2004-03-24	Human Genome Sciences Inc	TECHOLOGICAL MANIPULATION OF INTRACELLULAR SIALIZATION PATHS
CA2368734C (en)	1999-03-30	2005-08-23	Japan Tobacco Inc.	Method for preparing monoclonal antibody
JP4488579B2 (ja) *	1999-03-30	2010-06-23	日本たばこ産業株式会社	モノクローナル抗体の製造方法
CA2704600C (en)	1999-04-09	2016-10-25	Kyowa Kirin Co., Ltd.	A method for producing antibodies with increased adcc activity
ATE290879T1 (de)	1999-08-18	2005-04-15	Altarex Medical Corp	Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
US7147850B2 (en) *	1999-08-18	2006-12-12	Altarex Medical Corp.	Therapeutic binding agents against MUC-1 antigen and methods for their use
AU7743100A (en) *	1999-09-30	2001-04-30	Corixa Corporation	Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (fr)	2000-05-25	2002-07-12	Gervais Danone Sa	Utilisation de l. casei dans des compositions immunostimulantes
CA2424977C (en) *	2000-10-06	2008-03-18	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GB0029360D0 (en)	2000-12-01	2001-01-17	Univ Nottingham	Humanised antibodies and uses thereof
JPWO2002061118A1 (ja)	2001-02-01	2004-06-03	株式会社ヤクルト本社	発酵乳飲食品中のビフィドバクテリウム属細菌の腸内到達度評価方法
DE10139428A1 (de)	2001-08-17	2003-03-27	Nemod Immuntherapie Ag	Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
AU2002336981A1 (en) *	2001-08-17	2003-03-03	Charite	Glycoconjugates of sialic acid derivates, methods for their production and use thereof
MEP38608A (en) *	2001-10-22	2011-02-10	Merck Serono Sa	Gonadotrophins for folliculogenesis
GB0125473D0 (en)	2001-10-24	2001-12-12	Syngenta Ltd	Chemical process
EP1451217A4 (en) *	2001-11-20	2005-10-12	Atgen Co Ltd	NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
ES2524442T3 (es) *	2002-07-22	2014-12-09	Glycotope Gmbh	Procedimiento para la producción de una mucina (MUC1) inmunoestimulante
DK1530628T3 (da) *	2002-08-16	2011-01-10	Glycotope Gmbh	Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
DE10256900A1 (de)	2002-11-29	2004-06-24	Nemod Immuntherapie Ag	Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de)	2003-01-23	2004-08-12	Nemod Immuntherapie Ag	Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
SI1654353T1 (sl)	2003-08-18	2013-09-30	Glycotope Gmbh	Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
FR2861080B1 (fr) *	2003-10-20	2006-02-17	Lab Francais Du Fractionnement	Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) *	2003-11-14	2005-09-15	Atgen Co., Ltd.	Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
CN103627670B (zh) *	2004-02-13	2016-12-21	格莱克托普有限公司	高活性糖蛋白加工条件及其有效生产方法
JP4904266B2 (ja)	2004-07-26	2012-03-28	ザリサーチファウンデイションオブステイトユニバーシティーオブニューヨーク	抗−ｔｆ−抗原抗体の治療的使用
KR20080104143A (ko)	2006-02-14	2008-12-01	코닌클리케 필립스 일렉트로닉스 엔.브이.	광 디스크 판독용 비트 검출
WO2007124992A1 (en)	2006-04-28	2007-11-08	Unilever N.V.	Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
EP3539981A1 (en)	2006-09-10	2019-09-18	Glycotope GmbH	Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1900750A1 (en)	2006-09-18	2008-03-19	Glycotope Gmbh	Fully human high yield production system for improved antibodies
EP1911766A1 (en)	2006-10-13	2008-04-16	Glycotope Gmbh	Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) *	2006-11-10	2015-06-30	Glycotope Gmbh	Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
JP2011520435A (ja)	2008-05-13	2011-07-21	グリコトープゲーエムベーハー	発酵プロセス
US9079957B2 (en)	2009-04-16	2015-07-14	The University Of Tokyo	Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
EP2281844A1 (en)	2009-07-31	2011-02-09	Glycotope GmbH	MUC 1 antibodies
CA2897505A1 (en)	2013-01-18	2014-07-24	Glycotope Gmbh	Peptides for enhancing protein expression
JP2015138634A (ja)	2014-01-22	2015-07-30	株式会社オートネットワーク技術研究所	端子金具付き電線及びその製造方法

2007
- 2007-09-10 EP EP18188122.8A patent/EP3539981A1/en not_active Withdrawn
- 2007-09-10 AU AU2007294122A patent/AU2007294122B2/en active Active
- 2007-09-10 NZ NZ575974A patent/NZ575974A/en not_active IP Right Cessation
- 2007-09-10 ES ES11176197.9T patent/ES2620261T3/es active Active
- 2007-09-10 CA CA2662226A patent/CA2662226C/en active Active
- 2007-09-10 DK DK11176197.9T patent/DK2428224T3/en active
- 2007-09-10 RS RS20150158A patent/RS53861B1/sr unknown
- 2007-09-10 PL PL07818090.8T patent/PL2073842T5/pl unknown
- 2007-09-10 ES ES07818090T patent/ES2533964T5/es active Active
- 2007-09-10 CN CN201310176217.3A patent/CN103436574B/zh active Active
- 2007-09-10 EP EP20110176200 patent/EP2428225A3/en not_active Ceased
- 2007-09-10 EA EA200970263A patent/EA017622B1/ru not_active IP Right Cessation
- 2007-09-10 DK DK07818090.8T patent/DK2073842T4/da active
- 2007-09-10 HR HRP20150307TT patent/HRP20150307T1/hr unknown
- 2007-09-10 FI FIEP07818090.8T patent/FI2073842T4/fi active
- 2007-09-10 EP EP11176193A patent/EP2428223A3/en not_active Withdrawn
- 2007-09-10 KR KR1020157031066A patent/KR20150126730A/ko not_active Ceased
- 2007-09-10 SI SI200731634T patent/SI2073842T1/sl unknown
- 2007-09-10 KR KR1020097007469A patent/KR101603632B1/ko active Active
- 2007-09-10 EP EP11176197.9A patent/EP2428224B1/en active Active
- 2007-09-10 SG SG2011064987A patent/SG174792A1/en unknown
- 2007-09-10 WO PCT/EP2007/007877 patent/WO2008028686A2/en not_active Ceased
- 2007-09-10 BR BRPI0716997A patent/BRPI0716997B8/pt active IP Right Grant
- 2007-09-10 US US12/440,562 patent/US9051356B2/en active Active
- 2007-09-10 MX MX2009002388A patent/MX2009002388A/es active IP Right Grant
- 2007-09-10 EP EP07818090.8A patent/EP2073842B2/en active Active
- 2007-09-10 KR KR1020177004543A patent/KR20170021375A/ko not_active Ceased
- 2007-09-10 PT PT78180908T patent/PT2073842E/pt unknown
- 2007-09-10 JP JP2009527066A patent/JP5767779B2/ja active Active
2009
- 2009-03-08 IL IL197459A patent/IL197459A/en active IP Right Grant
- 2009-03-10 CU CU20090033A patent/CU23791A3/es active IP Right Grant
2010
- 2010-03-17 ZA ZA2010/01903A patent/ZA201001903B/en unknown
2015
- 2015-03-27 CY CY20151100305T patent/CY1116279T1/el unknown
- 2015-04-23 JP JP2015088247A patent/JP6166303B2/ja active Active
- 2015-05-04 US US14/703,498 patent/US10280230B2/en active Active
2017
- 2017-04-26 JP JP2017087053A patent/JP2017123879A/ja not_active Withdrawn
2019
- 2019-04-05 US US16/376,174 patent/US20190359731A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2620261T3 (es)	2017-06-28
DK2428224T3 (en)	2017-03-27
CN103436574B (zh)	2016-08-10
BRPI0716997B8 (pt)	2021-05-25
EP2428224A3 (en)	2012-05-09
SG174792A1 (en)	2011-10-28
AU2007294122A1 (en)	2008-03-13
JP2015146819A (ja)	2015-08-20
WO2008028686A2 (en)	2008-03-13
CA2662226C (en)	2020-08-04
JP5767779B2 (ja)	2015-08-19
CA2662226A1 (en)	2008-03-13
EP2428225A3 (en)	2012-05-09
IL197459A (en)	2015-08-31
JP6166303B2 (ja)	2017-07-19
IL197459A0 (en)	2011-08-01
US20100028947A1 (en)	2010-02-04
EP3539981A1 (en)	2019-09-18
ZA201001903B (en)	2010-11-24
EP2428223A2 (en)	2012-03-14
DK2073842T3 (da)	2015-04-13
DK2073842T4 (da)	2024-01-15
EA200970263A1 (ru)	2009-08-28
EP2428224A2 (en)	2012-03-14
KR101603632B1 (ko)	2016-03-16
EP2073842B1 (en)	2014-12-31
JP2010502204A (ja)	2010-01-28
US20190359731A1 (en)	2019-11-28
CN103436574A (zh)	2013-12-11
KR20090077911A (ko)	2009-07-16
BRPI0716997B1 (pt)	2020-06-02
US9051356B2 (en)	2015-06-09
BRPI0716997A8 (pt)	2019-02-05
MX2009002388A (es)	2009-06-02
EP2428225A2 (en)	2012-03-14
BRPI0716997A2 (pt)	2013-10-15
NZ575974A (en)	2012-03-30
HRP20150307T1 (hr)	2015-04-24
ES2533964T3 (es)	2015-04-16
EP2073842A2 (en)	2009-07-01
US20150368363A1 (en)	2015-12-24
JP2017123879A (ja)	2017-07-20
EP2428223A3 (en)	2012-05-16
US10280230B2 (en)	2019-05-07
AU2007294122B2 (en)	2013-03-07
KR20170021375A (ko)	2017-02-27
EP2073842B2 (en)	2023-10-18
WO2008028686A3 (en)	2008-06-12
CU23791A3 (es)	2012-03-15
EP2428224B1 (en)	2016-12-21
SI2073842T1 (sl)	2015-05-29
PT2073842E (pt)	2015-04-07
ES2533964T5 (es)	2024-05-09
FI2073842T4 (fi)	2024-01-15
CY1116279T1 (el)	2017-02-08
KR20150126730A (ko)	2015-11-12
EA017622B1 (ru)	2013-01-30
PL2073842T5 (pl)	2024-12-02
RS53861B1 (sr)	2015-08-31

Publication	Publication Date	Title
PL2073842T5 (pl)	2024-12-02	Zastosowanie ludzkich komórek pochodzących z białaczki szpikowej do ekspresji przeciwciał
HRP20181616T1 (hr)	2018-12-14	Potpuno ljudska anti-vap-1 monoklonska antitijela
IL193604A0 (en)	2011-08-01	Methods of using antibodies against human il-22
ZA201008952B (en)	2012-01-25	Compositions and methods of use for therapeutic antibodies
SI2949666T1 (sl)	2019-03-29	Človeška anti alfa-sinukleinska protitelesa
IL196701A0 (en)	2011-08-01	HUMAN ANTIBODIES TO ErbB2
PT3002298T (pt)	2019-11-20	Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
IL200610A0 (en)	2010-05-17	Human monoclonal anti-ip-10 antibodies and uses thereof
ZA201103723B (en)	2012-09-26	Human antibodies against human tissue factor
PL2631241T3 (pl)	2019-02-28	Sposób generowania białka i jego zastosowanie
PL2037950T3 (pl)	2014-09-30	Dodatkowe zastosowania medyczne białka antysekrecyjnego
IL212795A0 (en)	2011-07-31	Fully human antibodies against n-cadherin
ZA200901912B (en)	2010-06-30	Use of human cells of myeloid leukaemia origin for expression of antibodies
GB0605950D0 (en)	2006-05-03	Device for prediction of human or other mammalian labour onset
HRP20190159T1 (hr)	2019-03-22	Antitijela humanog anti-alfa-sinukleina
HU3177U (en)	2006-10-30	Electro-optical device for screening of skin diseases
HU0700076V0 (en)	2007-07-30	Device for covered introduction of scalpels
TWM300387U (en)	2006-11-01	Improved structure of cupulate holder
SG10202006468XA (en)	2020-08-28	Human antibodies against human tissue factor
HU0600626D0 (en)	2006-10-28	New medical use of mononucleosides